Title |
Clinical applications of PD-L1 bioassays for cancer immunotherapy
|
---|---|
Published in |
Journal of Hematology & Oncology, May 2017
|
DOI | 10.1186/s13045-017-0479-y |
Pubmed ID | |
Authors |
Delong Liu, Shuhang Wang, Wendy Bindeman |
Abstract |
Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1 expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 69 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 17% |
Student > Bachelor | 8 | 12% |
Student > Postgraduate | 7 | 10% |
Student > Master | 6 | 9% |
Student > Ph. D. Student | 6 | 9% |
Other | 13 | 19% |
Unknown | 17 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 30% |
Biochemistry, Genetics and Molecular Biology | 12 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Agricultural and Biological Sciences | 4 | 6% |
Unspecified | 2 | 3% |
Other | 7 | 10% |
Unknown | 19 | 28% |